The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection

Corrado Corti, Giuseppe Battaglia, Gemma Molinaro, Barbara Riozzi, Anna Pittaluga, Mauro Corsi, Manolo Mugnaini, Ferdinando Nicoletti, Valeria Bruno

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

Dual metabotropic glutamate 2/3 (mGlu2/3) receptor agonists have been examined with success in the clinic with positive proof of efficacy in several tests of anxiety and schizophrenia. Moreover, a large body of evidence has accumulated that these drugs have significant neuroprotective potential. An important discussion in the field deals with dissecting effects on mGlu2 versus effects on mGlu3 receptors, which is relevant for the potential use of subtype-selective agonists or allosteric activators. We addressed this issue using mGlu2 and mGlu3 receptor knock-out mice. We used mixed cultures of cortical cells in which astrocytes and neurons were plated at different times and could therefore originate from different mice. Cultures were challenged with NMDA for the induction of excitotoxic neuronal death. The mGlu2/3 receptor agonist, (-)-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), was equally neuroprotective in cultures containing neurons from wild-type, mGlu2-/-, or mGlu3-/- mice. Neuroprotection was instead abolished when astrocytes lacked mGlu3 receptors, unless neuronal mGlu2 receptors were also absent. The latter condition partially restored the protective activity of LY379268. Cultures in which neurons originated from mGlu2-/- mice were also intrinsically resistant to NMDA toxicity. In in vivo experiments, systemic administration of LY379268 protected striatal neurons against NMDA toxicity in wild-type and mGlu2-/- mice but not in mGlu3-/- mice. In addition, LY379268 was protective against nigrostriatal degeneration induced by low doses of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine only in mice lacking mGlu2 receptors. We conclude that neuroprotection by mGlu2/3 receptor agonists requires the activation of astrocytic mGlu3 receptors, whereas, unexpectedly, activation of mGlu2 receptors might be harmful to neurons exposed to toxic insults.

Original languageEnglish (US)
Pages (from-to)8297-8308
Number of pages12
JournalJournal of Neuroscience
Volume27
Issue number31
DOIs
StatePublished - Aug 1 2007

Fingerprint

Metabotropic Glutamate Receptors
LY 379268
Knockout Mice
Neurons
N-Methylaspartate
Astrocytes
Corpus Striatum
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Dicarboxylic Acids
Poisons
Hexanes
Neuroprotection
Schizophrenia
Anxiety
Cell Culture Techniques
Pharmaceutical Preparations
metabotropic glutamate receptor 2
metabotropic glutamate receptor 3

Keywords

  • Metabotropic glutamate receptors
  • MPTP
  • Neuroprotection
  • Neurotoxicity
  • Neurotrophic
  • Release

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection. / Corti, Corrado; Battaglia, Giuseppe; Molinaro, Gemma; Riozzi, Barbara; Pittaluga, Anna; Corsi, Mauro; Mugnaini, Manolo; Nicoletti, Ferdinando; Bruno, Valeria.

In: Journal of Neuroscience, Vol. 27, No. 31, 01.08.2007, p. 8297-8308.

Research output: Contribution to journalArticle

Corti, Corrado ; Battaglia, Giuseppe ; Molinaro, Gemma ; Riozzi, Barbara ; Pittaluga, Anna ; Corsi, Mauro ; Mugnaini, Manolo ; Nicoletti, Ferdinando ; Bruno, Valeria. / The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection. In: Journal of Neuroscience. 2007 ; Vol. 27, No. 31. pp. 8297-8308.
@article{334513a25df8466faaf80597d5abf006,
title = "The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection",
abstract = "Dual metabotropic glutamate 2/3 (mGlu2/3) receptor agonists have been examined with success in the clinic with positive proof of efficacy in several tests of anxiety and schizophrenia. Moreover, a large body of evidence has accumulated that these drugs have significant neuroprotective potential. An important discussion in the field deals with dissecting effects on mGlu2 versus effects on mGlu3 receptors, which is relevant for the potential use of subtype-selective agonists or allosteric activators. We addressed this issue using mGlu2 and mGlu3 receptor knock-out mice. We used mixed cultures of cortical cells in which astrocytes and neurons were plated at different times and could therefore originate from different mice. Cultures were challenged with NMDA for the induction of excitotoxic neuronal death. The mGlu2/3 receptor agonist, (-)-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), was equally neuroprotective in cultures containing neurons from wild-type, mGlu2-/-, or mGlu3-/- mice. Neuroprotection was instead abolished when astrocytes lacked mGlu3 receptors, unless neuronal mGlu2 receptors were also absent. The latter condition partially restored the protective activity of LY379268. Cultures in which neurons originated from mGlu2-/- mice were also intrinsically resistant to NMDA toxicity. In in vivo experiments, systemic administration of LY379268 protected striatal neurons against NMDA toxicity in wild-type and mGlu2-/- mice but not in mGlu3-/- mice. In addition, LY379268 was protective against nigrostriatal degeneration induced by low doses of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine only in mice lacking mGlu2 receptors. We conclude that neuroprotection by mGlu2/3 receptor agonists requires the activation of astrocytic mGlu3 receptors, whereas, unexpectedly, activation of mGlu2 receptors might be harmful to neurons exposed to toxic insults.",
keywords = "Metabotropic glutamate receptors, MPTP, Neuroprotection, Neurotoxicity, Neurotrophic, Release",
author = "Corrado Corti and Giuseppe Battaglia and Gemma Molinaro and Barbara Riozzi and Anna Pittaluga and Mauro Corsi and Manolo Mugnaini and Ferdinando Nicoletti and Valeria Bruno",
year = "2007",
month = "8",
day = "1",
doi = "10.1523/JNEUROSCI.1889-07.2007",
language = "English (US)",
volume = "27",
pages = "8297--8308",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "31",

}

TY - JOUR

T1 - The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration/ neuroprotection

AU - Corti, Corrado

AU - Battaglia, Giuseppe

AU - Molinaro, Gemma

AU - Riozzi, Barbara

AU - Pittaluga, Anna

AU - Corsi, Mauro

AU - Mugnaini, Manolo

AU - Nicoletti, Ferdinando

AU - Bruno, Valeria

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Dual metabotropic glutamate 2/3 (mGlu2/3) receptor agonists have been examined with success in the clinic with positive proof of efficacy in several tests of anxiety and schizophrenia. Moreover, a large body of evidence has accumulated that these drugs have significant neuroprotective potential. An important discussion in the field deals with dissecting effects on mGlu2 versus effects on mGlu3 receptors, which is relevant for the potential use of subtype-selective agonists or allosteric activators. We addressed this issue using mGlu2 and mGlu3 receptor knock-out mice. We used mixed cultures of cortical cells in which astrocytes and neurons were plated at different times and could therefore originate from different mice. Cultures were challenged with NMDA for the induction of excitotoxic neuronal death. The mGlu2/3 receptor agonist, (-)-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), was equally neuroprotective in cultures containing neurons from wild-type, mGlu2-/-, or mGlu3-/- mice. Neuroprotection was instead abolished when astrocytes lacked mGlu3 receptors, unless neuronal mGlu2 receptors were also absent. The latter condition partially restored the protective activity of LY379268. Cultures in which neurons originated from mGlu2-/- mice were also intrinsically resistant to NMDA toxicity. In in vivo experiments, systemic administration of LY379268 protected striatal neurons against NMDA toxicity in wild-type and mGlu2-/- mice but not in mGlu3-/- mice. In addition, LY379268 was protective against nigrostriatal degeneration induced by low doses of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine only in mice lacking mGlu2 receptors. We conclude that neuroprotection by mGlu2/3 receptor agonists requires the activation of astrocytic mGlu3 receptors, whereas, unexpectedly, activation of mGlu2 receptors might be harmful to neurons exposed to toxic insults.

AB - Dual metabotropic glutamate 2/3 (mGlu2/3) receptor agonists have been examined with success in the clinic with positive proof of efficacy in several tests of anxiety and schizophrenia. Moreover, a large body of evidence has accumulated that these drugs have significant neuroprotective potential. An important discussion in the field deals with dissecting effects on mGlu2 versus effects on mGlu3 receptors, which is relevant for the potential use of subtype-selective agonists or allosteric activators. We addressed this issue using mGlu2 and mGlu3 receptor knock-out mice. We used mixed cultures of cortical cells in which astrocytes and neurons were plated at different times and could therefore originate from different mice. Cultures were challenged with NMDA for the induction of excitotoxic neuronal death. The mGlu2/3 receptor agonist, (-)-2-oxa-4-aminocyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY379268), was equally neuroprotective in cultures containing neurons from wild-type, mGlu2-/-, or mGlu3-/- mice. Neuroprotection was instead abolished when astrocytes lacked mGlu3 receptors, unless neuronal mGlu2 receptors were also absent. The latter condition partially restored the protective activity of LY379268. Cultures in which neurons originated from mGlu2-/- mice were also intrinsically resistant to NMDA toxicity. In in vivo experiments, systemic administration of LY379268 protected striatal neurons against NMDA toxicity in wild-type and mGlu2-/- mice but not in mGlu3-/- mice. In addition, LY379268 was protective against nigrostriatal degeneration induced by low doses of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine only in mice lacking mGlu2 receptors. We conclude that neuroprotection by mGlu2/3 receptor agonists requires the activation of astrocytic mGlu3 receptors, whereas, unexpectedly, activation of mGlu2 receptors might be harmful to neurons exposed to toxic insults.

KW - Metabotropic glutamate receptors

KW - MPTP

KW - Neuroprotection

KW - Neurotoxicity

KW - Neurotrophic

KW - Release

UR - http://www.scopus.com/inward/record.url?scp=34547686245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547686245&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.1889-07.2007

DO - 10.1523/JNEUROSCI.1889-07.2007

M3 - Article

C2 - 17670976

AN - SCOPUS:34547686245

VL - 27

SP - 8297

EP - 8308

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 31

ER -